Last reviewed · How we verify
Gongjin-Dan
Gongjin-Dan is a Small molecule drug developed by Kyunghee University. It is currently FDA-approved.
At a glance
| Generic name | Gongjin-Dan |
|---|---|
| Sponsor | Kyunghee University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gongjin-Dan CI brief — competitive landscape report
- Gongjin-Dan updates RSS · CI watch RSS
- Kyunghee University portfolio CI
Frequently asked questions about Gongjin-Dan
What is Gongjin-Dan?
Gongjin-Dan is a Small molecule drug developed by Kyunghee University.
Who makes Gongjin-Dan?
Gongjin-Dan is developed and marketed by Kyunghee University (see full Kyunghee University pipeline at /company/kyunghee-university).
What development phase is Gongjin-Dan in?
Gongjin-Dan is FDA-approved (marketed).
Related
- Manufacturer: Kyunghee University — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing